PublisherInfo				
PublisherName		BioMed Central		
PublisherLocation		London		
PublisherImprintName	$\Box$	BioMed Central		

## New genetic vaccines using self-replicative RNA

ArticleInfo		
ArticleID	:	4079
ArticleDOI	:	10.1186/gb-spotlight-20010510-01
ArticleCitationID	:	spotlight-20010510-01
ArticleSequenceNumber	:	150
ArticleCategory	:	Research news
ArticleFirstPage	:	1
ArticleLastPage	:	2
ArticleHistory	:	RegistrationDate : 2001–05–10 OnlineDate : 2001–05–10
ArticleCopyright	:	BioMed Central Ltd2001
ArticleGrants	:	
ArticleContext		130592211

## **Tudor** Toma

Email: ttoma@mail.dntis.ro

The discovery that naked plasmid DNA can elicit humoral and cellular immunity has prompted the development of genetic vaccines against many viruses for which no prevention currently exists. In the 1 May Journal of Infectious Diseases, Marina Fleeton and colleagues from the Karolinska Institute in Stockholm suggest the possibility of using the recombinant alpha virus RNA molecule - which replicates in the cytoplasm of transfected cells - as a novel approach in genetic vaccine development.

Fleeton *et al.* immunized mice with recombinant Semliki Forest virus RNA encoding envelope proteins from influenza A, RSV or tick-borne encephalitis virus and found that antigen-specific antibody responses occurred after vaccination. IgG isotyping indicated that predominantly Th1 type immune responses were induced following immunization with RNA encoding the RSV F protein, suggesting protection against RSV infection had been generated. Challenge infection showed that RNA immunization had elicited significant levels of protection against the 3 model virus diseases (*J Infect Dis* 2001, **183**:1395-1398).

In contrast to the viral vector approach the rSFV RNA vaccine contains none of the highly immunogenic viral structural components. This may be of considerable benefit in situations where booster immunizations are desired.

## References

- 1. Fleeton MN, Chen M, Berglund P, Rhodes G, Parker SE, Murphy M, Atkins GJ, Liljestrom P: Self-replicative RNA vaccines elicit protection against influenza a virus, respiratory syncytial virus, and a tickborne encephalitis virus. *J Infect Dis* 2001, 183:1395-1398., [http://www.journals.uchicago.edu/JID/journal/issues/v183n9/001273/brief/001273.abstract.html]
- 2. Karolinska Institute, [http://info.ki.se/index\_en.html]

This PDF file was created after publication.